Amylin could not take this to market on their own and this is part of the reason they sold out. This only makes sense. Bydureon is a great drug and very effective in controlling BS in T2 diabetes. The big draw back is the mixing and injecting. Once the pen is approved it will be more widely accepted. Bydureon and Afrezza are not at all similiar and one will not impact the sales of the other IMO. I see the same thing happening to Mannkind (alliances, partnerships or selling out) to take Afrezza to market. If MNKD decides to do it alone it will be a struggke.
